BOTOX COSMETIC POWDER FOR SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

ONABOTULINUMTOXINA

Disponibbli minn:

ABBVIE CORPORATION

Kodiċi ATC:

M03AX01

INN (Isem Internazzjonali):

BOTULINUM TOXIN

Dożaġġ:

50UNIT

Għamla farmaċewtika:

POWDER FOR SOLUTION

Kompożizzjoni:

ONABOTULINUMTOXINA 50UNIT

Rotta amministrattiva:

INTRAMUSCULAR

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Schedule D

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0151557003; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2022-10-03

Karatteristiċi tal-prodott

_Botox Cosmetic (onabotulinumtoxinA)_
_Page 1 of 27_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BOTOX COSMETIC
®
onabotulinumtoxinA
_Clostridium botulinum_ type A neurotoxin complex (900kD)
Sterile vacuum-dried concentrate powder for solution for injection
50 and 100 Allergan units per vial, intramuscular
Pharmaceutical Standard: Ph. Eur.
Neuromuscular Paralytic Agent (ATC Code: M03AX01)
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, QC H4S 1Z1
Date of Initial Approval:
APR 04, 2001
Date of Revision:
NOV 04, 2022
Submission Control No: 263461
_ _
_Botox Cosmetic (onabotulinumtoxinA) _
_Page 2 of 27 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Consideration
06/2020
7 WARNINGS AND PRECAUTIONS
06/2020
8 ADVERSE REACTIONS, 8.5 Post Marketing Adverse Reactions
06/2020
9 DRUG INTERACTIONS, 9.4 Drug-Drug Interaction
08/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................5
4
DOSAGE AND
ADMINISTRATION..........................................................